

AD _____

Award Number: W81XWH-04-1-0883

TITLE: Zebrafish Models of BCR-ABL-Induced Leukemogenesis

PRINCIPAL INVESTIGATOR: A. Thomas Look, M.D.

CONTRACTING ORGANIZATION: Dana-Farber Cancer Institute
Boston, MA 02115

REPORT DATE: October 2005

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20060503121

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
<small>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</small>					
1. REPORT DATE 01-10-2005		2. REPORT TYPE Final		3. DATES COVERED 20 Sep 2004 –19 Sep2005	
4. TITLE AND SUBTITLE Zebrafish Models of BCR-ABL-Induced Leukemogenesis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0883	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) A. Thomas Look, M.D.				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Dana-Farber Cancer Institute Boston, MA 02115				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT We plan to study the consequences of BCR-ABL expression in myeloid cells, using the zebrafish model system. The fundamental genetic mechanisms that control hematopoiesis are well conserved, and many of the genes known to regulate these processes in mammals have been recently identified in zebrafish. Advantages of the zebrafish provide an unparalleled opportunity to identify specific genes whose mutational inactivation blocks BCR-ABL activity, and whose products therefore serve as potential targets for the development of small molecule inhibitors that could be used in treatment of CML. Determination of the patho-physiologic significance of BCR-ABL in transgenic zebrafish models and stable transgenic zebrafish models for BCR-ABL induced leukemia will establish the necessary groundwork that will be valuable in conducting future modifier screens.					
15. SUBJECT TERMS NOT PROVIDED					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	6	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4.
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	6
Conclusions.....	6
References.....	6

Introduction

The goal of our proposal (CM030067; Zebrafish models of BCR-ABL induced leukaemogenesis) is to determine the pathophysiologic significance of BCR-ABL in transgenic zebrafish models, establishing the necessary groundwork that will be valuable in conducting future modifier screens.

It is generally believed that Chronic Myelogenous Leukemia (CML) develops when a single, pluripotential, hematopoietic stem cell acquires a Ph chromosome carrying the BCR-ABL fusion gene, conferring a proliferative advantage over normal hematopoietic elements and allows the Ph-positive clone gradually to displace residual normal hematopoiesis (Eaves et al. 1997, 2001). CML generally requires allogeneic bone marrow transplantation for cure, but efforts to extend this form of treatment to all patients with CML have been thwarted by the lack of suitable donors and risk of potentially lethal graft-versus-host disease (GVHD). The recent introduction into clinical practice of a tyrosine kinase inhibitor (imatinib) that specifically blocks the enzymatic action of the BCR-ABL fusion protein promises to be a major contribution to the management of CML. However, no information on long-term survival with imatinib is available yet. Furthermore, observation of imatinib resistance even in chronic phase (Hochhaus et al. 2002) and of residual disease in complete cytogenetic responders, casts doubt on the life prolonging potential of imatinib monotherapy.

Studies in zebrafish models complement research in human cell lines and mouse models because of the inherent capacity of zebrafish to accommodate genome-wide enhancer-suppressor screens for modifier genes in critical pathways that exacerbate abnormal myelopoietic phenotypes or restore normal hematopoiesis. This advantage provides an unparalleled opportunity to identify specific genes whose mutational inactivation blocks BCR-ABL activity, and whose products therefore serve as potential targets for the development of small molecule inhibitors that could be used in treatment of CML.

Body

1. We hypothesized that the expression of BCR-ABL in zebrafish embryos under the control of a myeloid cell specific promoter will cause abnormal proliferation and expansion of the number of granulocytes and their progenitors through changes involving cell growth, viability and differentiation. We will take advantage of the zebrafish model system to directly visualize myeloid progenitors in the developing embryo in vivo, through the analysis of transgenic zebrafish microinjected (as fertilized eggs) with a BCR-ABL protein.

2. We hypothesized that stable lines of transgenic zebrafish expressing BCR-ABL will develop hypercellular kidney marrow, splenomegaly, and neutrophilia resembling a myeloproliferative disorder. The development of stable transgenic lines is a critical step in the future goal of conducting modifier screens to discover additional important genes in the oncogenic pathway used by BCR-ABL. Insight into this pathway may lead to the identification of modifier genes that can serve as potential drug targets.

Objectives:

Aim 1. To define the spectrum of phenotypes, including a potential proliferative and survival advantage, induced by constitutive expression of BCR-ABL in developing myeloid cells in vivo.

Aim 2. Establish stable transgenic lines of zebrafish overexpressing BCR-ABL in myeloid stem and progenitor cells and monitor these fish for the development of myeloproliferative syndrome and AML.

Key Research Accomplishments

The zebrafish *pu.1* promoter fragment we have isolated and used to generate a *zpu.1-GFP* transgenic line is active not only in myeloid progenitor cells but also in the trunk musculature. This ectopic expression will not pose a problem for our investigations. However, in the *zpu.1-GFP* transgenics, GFP is also detectable at the one cell stage of fertilized embryos indicating maternal contribution (Hsu et al. 2004). A similar maternal expression of GFP has been detected using an *mpo* promoter (*FmpoP*) fragment isolated from the pufferfish *takifugu rubripes* (Grabher, unpublished). Previous experience from our lab and others has demonstrated that such an early expression of a highly potent oncogene such as BCR-ABL is lethal to the animals before or during gastrulation.

For optimal time management we have thus decided to start preparations for Aim 2 before engaging Aim 1. In order to avoid an early lethal BCR-ABL phenotype, we designed a conditional vector applying the *cre-lox* system that has been established for zebrafish in our laboratory (Langenau et al. 2005). In order to be able to exchange different promoter elements easily, we have adapted the GATEWAY cloning system (Invitrogen). Adaptation of this highly efficient cloning system was tedious but was successful. So far we succeeded in designing a conditional vector containing a *FmpoP-lox-GFPpA-lox-BCR-ABLpA* expression cassette. This entire expression cassette is flanked by two I-SceI meganuclease restriction sites, which will increase transgenesis frequencies when co-injected with the I-SceI enzyme (Grabher et al. 2004). We successfully injected several hundred embryos with this vector and have pre-screened them for promising putative founder fish based on GFP expression. Approximately, one hundred putative founder fish are currently growing and will reach sexual maturity within the next month when we will start screening for transgene transmission to the offspring to identify germline founders. We are currently generating the same vector containing the *zpu.1* promoter fragment in place of the *FmpoP* to establish additional transgenics driving BCR-ABL under the control of this promoter upon excision of the *lox-GFPpA-lox* cassette by injection of *cre* mRNA into one-cell stage transgenic embryos or mating of BCR-ABL transgenics to a heat-shock inducible *cre* transgenic line. Following injections of several hundred embryos with *zpu.1-lox-GFPpA-lox-BCR-ABLpA* vector and prescreening for promising putative founders, we will engage in the transient experiments described as Aim 1 in the original proposal.

Reportable Outcomes

We have successfully designed conditional expression vectors using two different promoter fragments (FmpoP and zpu.1) to drive BCR-ABL in a conditional manner using the *cre-lox* system. Furthermore we are in the process of generating stable transgenic lines with both of these transgenic vectors.

Conclusions

We are on track for generating stable transgenic animals expressing BCR-ABL in a conditional manner. We hypothesize that stable lines of transgenic zebrafish expressing BCR-ABL will develop hypercellular kidney marrow, splenomegaly, and neutrophilia resembling a myeloproliferative disorder. Lines expressing BCR-ABL in myeloid cells are necessary for the long-term goal of conducting modifier screens to discover novel important genes that are essential to the oncogenic pathways used by BCR-ABL. While putative founder fish are growing we will initiate the transient studies of Aim 1.

References

- Eaves CJ, Eaves AC. Progenitor cell dynamics. In: Carella AM, Daley GQ, Eaves CJ, Goldman JM, Hehlmann R, eds. Chronic myeloid leukaemia: biology and treatment. London: Martin Dunitz, 2001:73-100.
- Eaves CJ, Eaves AC. Stem cell kinetics. *Baillieres Clin Haematol* 1997;10:233-57.
- Hochhaus A, Kreil S, Corbin AS, La Rosee P, Müller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. *Leukemia* 2002; 16: 2190-2196.
- Grabher, C., J. S. Joly, et al. (2004). "Highly efficient zebrafish transgenesis mediated by the meganuclease I-SceI." *Methods Cell Biol* 77: 381-401.
- Hsu, K., D. Traver, et al. (2004). "The pu.1 promoter drives myeloid gene expression in zebrafish." *Blood* 104(5): 1291-7.
- Langenau, D. M., H. Feng, et al. (2005). "Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia." *Proc Natl Acad Sci U S A* 102(17): 6068-73.